The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity

Sarah L. Tan, Tessa Potezny, Jordan Y. Li

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Abstract

Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.
Original languageEnglish
Pages (from-to)216-217
Number of pages2
JournalNephrology
Volume27
Issue number2
DOIs
Publication statusPublished - Feb 2022

Keywords

  • crescentic IgA nephropathy
  • ANCA-positive vasculitis
  • rituximab
  • MPO-ANCA
  • cyclophosphamide

Fingerprint

Dive into the research topics of 'The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity'. Together they form a unique fingerprint.

Cite this